.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A recent ICMR study highlights the BPaL TB regimen India. This evaluation, published in the IJMR, shows that shorter treatment cycles for drug-resistant tuberculosis are cost-effective. Researchers at the NIRT compared six-month regimens against longer protocols. Their findings suggest these protocols enhance health outcomes and reduce costs.
The study focused on the BPaL regimen, including Bedaquiline, Pretomanid, and Linezolid. Additionally, it assessed the BPaLM regimen, which incorporates Moxifloxacin. The BPaL protocol is both effective and economical. The healthcare system saves Rs 379 per patient for every additional quality-adjusted life year gained. Consequently, this transition benefits both patients and providers.
Furthermore, the BPaLM regimen showed high cost-effectiveness. The analysis indicates an additional expenditure of just Rs 37 per patient per QALY. Both options offer a sustainable alternative to standard 9-to-11-month plans. Notably, these results underscore the importance of resource optimization.
Managing drug-resistant tuberculosis is traditionally very challenging. Long treatment durations often cause adverse effects and poor adherence. However, shorter all-oral regimens address these issues by simplifying the process. They reduce patient morbidity and enable a faster return to life. Moreover, these plans lower the overall burden on clinics. By aligning with national priorities, these regimens support TB elimination.
Q1: What is the primary advantage of the BPaL regimen?
The BPaL regimen reduces treatment duration from 18-20 months to just six months. Additionally, it is an all-oral treatment, which improves patient adherence.
Q2: How much does the health system save with the BPaL TB regimen India?
According to the ICMR study, the BPaL regimen saves Rs 379 per patient for each additional quality-adjusted life year gained.
Q3: Is the BPaLM regimen cost-effective?
Yes, the BPaLM regimen is highly cost-effective, costing only Rs 37 more per patient per additional QALY gained.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ICMR study finds 6-month all-oral BPaL and BPaLM regimens for MDR-TB are highly cost-effective and improve patient outcomes compared to current long-term pl...
6 months ago
A comprehensive analysis of continuous glucose monitoring systems under European Medical Device Regulation 2017/745, examining conformity assessment challenges, Notified Body backlogs, EUDAMED rollout delays, and the critical need for transparent post-market surveillance.
Today
A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday
A comprehensive meta-analysis shows digital health technologies significantly improve 6-minute walk distance and peak oxygen uptake in chronic heart failure patients, highlighting the clinical promise of structured remote cardiac rehabilitation.
Today
Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today
The Supreme Court of India has sharply criticized the Food Safety and Standards Authority of India for delaying front-of-package warning labels. With non-communicable diseases causing over 6 million deaths annually, clear nutritional warnings are critical to combat childhood obesity, diabetes, and cardiovascular risk.
Today
